Luoxin Pharmaceuticals Group Stock Co Ltd (002793) — Tangible Net Worth Ratio
Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has a Tangible Net Worth Ratio of 49.6% as of March 2026. This metric is calculated by deducting intangible assets (CN¥592.16 Million) from net assets (CN¥1.18 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See working capital position of Luoxin Pharmaceuticals Group Stock Co Lt to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Luoxin Pharmaceuticals Group Stock Co Ltd Tangible Net Worth Ratio (2011–2025)
This chart shows how Luoxin Pharmaceuticals Group Stock Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 49.6%, reflecting net assets of CN¥1.18 Billion with intangible assets of CN¥592.16 Million CNY. See 002793 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 002793 market cap.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 51.5% | CN¥1.24 Billion | CN¥599.46 Million | CN¥3.73 Billion | ▼ -2.3 pp |
| 2024 | 53.8% | CN¥1.46 Billion | CN¥674.40 Million | CN¥4.34 Billion | ▼ -19.0 pp |
| 2023 | 72.7% | CN¥2.57 Billion | CN¥701.15 Million | CN¥5.12 Billion | ▼ -7.7 pp |
| 2022 | 80.4% | CN¥3.31 Billion | CN¥646.47 Million | CN¥8.11 Billion | ▼ -5.8 pp |
| 2021 | 86.3% | CN¥4.74 Billion | CN¥650.29 Million | CN¥9.50 Billion | ▲ +0.1 pp |
| 2020 | 86.2% | CN¥4.35 Billion | CN¥601.88 Million | CN¥7.72 Billion | ▼ -0.9 pp |
| 2019 | 87.0% | CN¥3.96 Billion | CN¥513.86 Million | CN¥7.46 Billion | ▲ +17.2 pp |
| 2018 | 69.9% | CN¥909.89 Million | CN¥274.13 Million | CN¥1.40 Billion | ▼ -4.8 pp |
| 2017 | 74.6% | CN¥754.19 Million | CN¥191.39 Million | CN¥898.93 Million | ▼ -24.4 pp |
| 2016 | 99.0% | CN¥698.33 Million | CN¥6.84 Million | CN¥812.89 Million | ▲ +0.2 pp |
| 2015 | 98.8% | CN¥339.50 Million | CN¥4.06 Million | CN¥549.60 Million | ▲ +22.0 pp |
| 2014 | 76.8% | CN¥315.46 Million | CN¥73.16 Million | CN¥447.86 Million | ▼ -23.2 pp |
| 2013 | 100.0% | CN¥251.50 Million | CN¥17.00K | CN¥363.30 Million | ▲ +0.1 pp |
| 2012 | 99.9% | CN¥205.54 Million | CN¥247.00K | CN¥372.31 Million | ▲ +3.9 pp |
| 2011 | 96.0% | CN¥151.87 Million | CN¥6.13 Million | CN¥271.94 Million | — |